Sangamo Initiates Clinical Trial of Novel Therapy for Diabetic Neuropathy
Sangamo BioSciences has initiated a Phase I clinical trial of SB-509, a novel therapeutic designed to protect and stimulate the regeneration of peripheral nerve function in diabetics suffering from peripheral neuropathy.
The multicenter study is designed to evaluate clinical safety of SB-509 in diabetics with mild-to-moderate diabetic peripheral sensory motor neuropathy in the legs. The FDA cleared an investigational new drug (IND) filing for the single-blind, placebo-controlled, dose-escalation trial in February 2005.
The trial began with the screening and treatment of the first patient at the Diabetes and Glandular Disease Clinic in San Antonio, Texas. Other trial sites are expected to begin recruitment shortly and Sangamo expects to have up to a total of 4 sites participating in the study.
Upcoming Events
-
21Oct